Breast Cancer

Latest News

January 1st 1995

NIH and Private Industry in Legal Battle over Breast Cancer Gene Patent

WASHINGTON--The National Institutes of Health (NIH) is disputing the commercial rights to the newly discovered breast cancer gene BRCA1. In a move that could affect how much women pay for screening when such a test becomes available, scientists at the University of Utah and Myriad Genetics, Inc. failed to include NIH as a collaborator when it applied to patent the gene. The NIH has filed a counter application.

November 1st 1994

A Multidisciplinary Approach to the Management of Patients With Metastatic Disease to the Bone

Breast Cancer

Latest News

CME Content

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Louisiana Oncology Society

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Missouri Oncology Society

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Iowa Oncology Society

Washington State Medical Oncology Society

Indiana Oncology Society

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Community Oncology Connections™: Bridging Academic and Community Expertise in Evidence-Based Care for Desmoid Tumors | South Carolina Oncology Society

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Wisconsin Association of Hematology and Oncology

Missouri Oncology Society

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Arkansas Association of Cancer Professionals

New Mexico Society of Clinical Oncology

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | Wyoming State Oncology Society & Montana State Oncology Society

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | North Carolina Oncology Association

Project ECHO®: Advancing Personalized Care Across the HR+/HER2– Breast Cancer Continuum

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Indiana Oncology Society

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | Rhode Island Oncology Society

Nevada Oncology Society

Show Me the Data: Immunotherapy Across the Hepatobiliary Cancer Continuum—From Embolization-Eligible HCC to Advanced Biliary Tract Cancers

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Colorado Oncology Society

Montana State Oncology Society

Wisconsin Association of Hematology and Oncology

Rhode Island Oncology Society

21st Annual New York Lung Cancers Symposium®

South Carolina Oncology Society

Texas Society of Clinical Oncology

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

9th Annual School of Nursing Oncology™

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Medical Crossfire®: TKIs and ADCs in HER2-Mutant NSCLC – Which Class, Which Line?

Kentucky Society of Clinical Oncology

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways from Limited-Stage Through Relapsed Disease

Empire State Hematology & Oncology Society (New York)

Minnesota Society of Clinical Oncology

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Navigating the Adverse Event Landscape in HER2+ GEA Therapy

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical Data

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary Care

Real-World Insights on Advances in the Management of Myeloproliferative Neoplasms: How the Experts Apply the Latest Developments to Clinical Practice

Tumor Board™: Navigating a New Era of Innovation and Expanding Options in NMIBC

“D” is for Diagnosis: Decoding a Difficult Thoracic Malignancy—Piecing Together a Rare Diagnosis, Preparing for Tomorrow’s Treatments

(CPE Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC

Expanding Options, Evolving Challenges in Advanced HR+/HER2– Breast Cancer: How Experts Apply the Latest Data

Medical Crossfire®: Optimizing 𝘌𝘚𝘙1 Mutation Detection and Next-Generation Endocrine Therapy Integration in HR+/HER2– Breast Cancer

(CPE Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Virtual Hot Seat: How the Experts Target the PI3K/AKT/mTOR Pathway in HR+/HER2– Metastatic Breast Cancer

OncoBytes Adaptive Learning Pathways: Personalizing Treatment Plans to Optimize Adjuvant Therapy in Early-Stage HR+/HER2- Breast Cancer

Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer

Medical Crossfire® — From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas

Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities

Oncology Town Hall: Translating the Latest Updates Into the Care of Patients With AML in Community Practice

Trending on CancerNetwork

FDA Approves Dostarlimab in Previously Untreated Locally Advanced Rectal Cancer

Ris-Rez Produces Anti-Tumor Activity in Extensive-Stage SCLC

FDA Accepts NDA for UGN-103 in Recurrent Low-Grade Intermediate-Risk NMIBC

Sequencing CAR T-Cell Therapy and Bispecifics to Preserve T-Cell Fitness

Neoadjuvant Radiotherapy Challenges the Surgery-First Paradigm in Breast Cancer